Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

CSL312_3003 Sikkerheds- og farmakokinetisk undersøgelse hos forsøgspersoner i alderen 2 til 11 år med arvelig angioødem

6. maj 2026 opdateret af: CSL Behring

Et fase 3 åbent studie til evaluering af sikkerhed, farmakokinetik, farmakodynamik og effektivitet af CSL312 (Garadacimab) i profylaktisk behandling af arveligt angioødem hos pædiatriske forsøgspersoner i alderen 2 til 11 år

Formålet med denne undersøgelse er at undersøge sikkerheden, PK/PD og effektiviteten af ​​SC CSL312 til profylaktisk behandling af pædiatriske personer med HAE.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

22

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Australien
      • Campbelltown, Australien, NSW 2560
        • Campbelltown Hospital, Western Sydney University
  • Canada
      • Ottawa, Canada, K1H1E4
        • Ottawa Allergy Research Corp
  • Forenede Stater
    • Arizona
      • Litchfield Park, Arizona, Forenede Stater, 85340
        • Research Solutions of Arizona
      • Scottsdale, Arizona, Forenede Stater, 85251
        • Medical Research of Arizona
    • California
      • Orange, California, Forenede Stater, 92868
        • Donald S. Levy M.D.
      • Santa Monica, California, Forenede Stater, 90404
        • Raffi Tachdjian MD, Inc.
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45236
        • Bernstein Clinical Research
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • PennState Health Milton S. Hershey Medical Center
    • Texas
      • Dallas, Texas, Forenede Stater, 75231
        • AARA Research Center
  • Israel
      • Ashkelon, Israel, 7830604
        • Barzilai University Medical Center
  • Tyskland
      • Berlin, Tyskland, 12203
        • Charité - Universitätsmedizin Berlin
      • Frankfurt am Main, Tyskland, 60590
        • Universitatsklinikum Frankfurt
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60596
        • HZRM Hämophilie Zentrum Rhein Main GmbH

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn

Tager imod sunde frivillige

Ingen

Beskrivelse

Inklusionskriterier:

  1. Mand eller kvinde
  2. I alderen 2 til 11 år inklusive, med kropsvægt ≥ 10. percentil baseret på alder
  3. Diagnosticeret med klinisk bekræftet C1-INH HAE
  4. Oplevet ≥ 2 HAE-anfald i løbet af de 6 måneder før screening

Ekskluderingskriterier:

  1. Samtidig diagnosticering af en anden form for angioødem, såsom idiopatisk eller erhvervet angioødem, tilbagevendende angioødem forbundet med urticaria eller HAE type III
  2. Eventuelle forudplanlagte større operationer eller procedurer under den kliniske undersøgelse
  3. Brug af C1-INH-produkter, androgener, antifibrinolytika, godkendte eller fremtidige godkendte lægemidler eller anden medicin med små molekyler til rutinemæssig profylakse mod HAE-angreb
  4. Deltagelse i et andet interventionelt klinisk studie

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: CSL312
Alder 2-5 år og 6-11 år vil have specifikke subkutane doseringsskemaer
Biologisk: CSL312
Fuldt humant immunoglobulin G subklasse 4/lambda rekombinant inhibitor monoklonalt antistof administreret subkutant (SC)
Andre navne:
  • Garadacimab

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Treatment Emergent Adverse Events (TEAE)
Tidsramme: Up to Month 12
Up to Month 12
Percentage of Participants With TEAE
Tidsramme: Up to Month 12
The percentage of participants was rounded to one place of decimal.
Up to Month 12
Number of TEAE
Tidsramme: Up to Month 12
Up to Month 12
TEAE Rates Per Injection
Tidsramme: Up to Month 12
The TEAE rate per injection was calculated as the number of TEAE/ number of injections. The number of injections was defined as the total injections a participant received during the Safety Evaluation Period under the dosing regimen to which the TEAE was assigned.
Up to Month 12
TEAE Rates Per Participant-Year
Tidsramme: Up to Month 12
The TEAE rate per participant year was calculated as number of TEAEs/ participant years. Participant-years of exposure were calculated as the sum of each participant's exposure duration (in years) under the specified dosing regimen or overall. For the time assigned to a dosing regimen, each study day was counted under the corresponding regimen.
Up to Month 12
Maximum Concentration (Cmax) of CSL312 at Steady-state
Tidsramme: Up to Month 12
Up to Month 12
Trough Concentration (Ctrough) of CSL312 at Steady-state
Tidsramme: At Months 3, 4, 6, 9, 10, and 12
At Months 3, 4, 6, 9, 10, and 12
Time to Maximum Concentration (Tmax) of CSL312 at Steady-State
Tidsramme: Up to Month 12
Up to Month 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time-normalized Number of HAE Attacks Per Month
Tidsramme: Up to Month 12
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: [Number of HAE attacks / Length of participant treatment in days] * 30.4375.
Up to Month 12
Time-normalized Number of HAE Attacks Per Year
Tidsramme: Up to Month 12
Time-normalized number of HAE attacks per year during treatment was calculated per participant as: [Number of HAE attacks / Length of participant treatment in days] * 365.25.
Up to Month 12
Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Month
Tidsramme: Up to Month 12

The time-normalized number of HAE attacks per month treated with on-demand treatment were calculated as follows:

[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days] ∗ 30.4375.
Up to Month 12
Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Year
Tidsramme: Up to Month 12

The time-normalized number of HAE attacks per year treated with on-demand treatment were calculated as follows:

[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days] ∗ 365.25.
Up to Month 12
Time-normalized Number of Moderate and/or Severe HAE Attacks Per Month
Tidsramme: Up to Month 12
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: [number of moderate or severe HAE attacks / length of participant treatment in days] * 30.4375.
Up to Month 12
Time-normalized Number of Moderate and/or Severe HAE Attacks Per Year
Tidsramme: Up to Month 12
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: [number of moderate or severe HAE attacks / length of participant treatment in days] * 365.25.
Up to Month 12
Percentage Reduction in the Time-normalized Number of HAE Attacks
Tidsramme: Up to Month 12
The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as follows: 100*[ 1 - (Time-normalized number of HAE attacks per month during treatment period/Time-normalized number of HAE attacks per month from historical data)].
Up to Month 12
Number of Participants Experiencing at Least Greater Than or Equal to (>=) 50 Percent (%), >= 70%, >= 90%, or Equal to 100% (Attack-free) Reduction in the Time-normalized Number of HAE Attacks
Tidsramme: Up to Month 12
A participant was classified as a responder if the percentage reduction in the time-normalized number of HAE attacks under treatment compared to the time-normalized number of HAE attacks documented in the medical records was >= 50%. Percent Reduction = 100 * [1 - (time-normalized number of HAE attacks during corresponding time window / time-normalized number of HAE attacks based on historical data)]. Here number of participants experiencing at least >= 50%, >= 70%, >= 90%, or equal to 100% (Attack-free) reduction in the time-normalized number of HAE attacks are reported. The number of responders at each reduction category have been reported.
Up to Month 12
Number of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
Tidsramme: Up to Month 12
Up to Month 12
Percentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
Tidsramme: Up to Month 12
The percentage of participants was rounded to one decimal place.
Up to Month 12
Number of Participants With TEAE by Severity
Tidsramme: Up to Month 12

Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where:

Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
Up to Month 12
Percentage of Participants With TEAE by Severity
Tidsramme: Up to Month 12

Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where:

Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one place of decimal.
Up to Month 12
Number of Participants With Anti-CSL312 Antibodies
Tidsramme: At Day 1, Months 6 and 12
At Day 1, Months 6 and 12
Percentage of Participants With Anti-CSL312 Antibodies
Tidsramme: At Day 1, Months 6 and 12
The percentage of participants was rounded to one place of decimal.
At Day 1, Months 6 and 12
Number of Participants With Adverse Events of Special Interest (AESI)
Tidsramme: Up to Month 12
AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with a Standardized MedDRA Query (SMQ).
Up to Month 12
Percentage of Participants With AESI
Tidsramme: Up to Month 12
AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with an SMQ. The percentage of participants was rounded to one place of decimal.
Up to Month 12
FXIIa-mediated Kallikrein Activity
Tidsramme: At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10
At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10
Percent of Baseline FXIIa-mediated Kallikrein Activity
Tidsramme: At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10
Percent of Baseline at Visit [i] = 100 * (actual value at Visit [i] / Baseline value), where Baseline is defined as the most recent, non-missing value before the first IP administration (including unscheduled visits). Here unit of measure is Percent (%) of FXIIa-mediated Kallikrein Activity.
At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10
Number of Participants With Laboratory Findings Reported as AE
Tidsramme: Up to Month 12
Up to Month 12
Percentage of Participants With Laboratory Findings Reported as AE
Tidsramme: Up to Month 12
The participant data were rounded to one decimal place.
Up to Month 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

CSL Behring

Efterforskere

  • Studieleder: Study Director, CSL Behring

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. maj 2023

Primær færdiggørelse (Faktiske)

19. november 2025

Studieafslutning (Faktiske)

19. november 2025

Datoer for studieregistrering

Først indsendt

4. april 2023

Først indsendt, der opfyldte QC-kriterier

17. april 2023

Først opslået (Faktiske)

19. april 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. maj 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • CSL312_3003
  • 2022-502386-13-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

CSL vil overveje anmodninger om at dele individuelle patientdata (IPD) fra systematiske gennemgangsgrupper eller bonafide forskere. Kontakt CSL på clinicaltrials@cslbehring.com for information om processen og kravene til indsendelse af en frivillig anmodning om datadeling for IPD.

Gældende landespecifikke privatliv og andre love og regler vil blive taget i betragtning og kan forhindre deling af IPD.

Hvis anmodningen godkendes, og forskeren har indgået en passende datadelingsaftale, vil IPD, der er blevet passende anonymiseret, være tilgængelig.

IPD-delingstidsramme

IPD-anmodninger kan indsendes til CSL tidligst 12 måneder efter offentliggørelsen af ​​resultaterne af denne undersøgelse via en artikel, der er tilgængelig på en offentlig hjemmeside.

IPD-delingsadgangskriterier

Anmodninger kan kun fremsættes af systematiske bedømmelsesgrupper eller bonafide forskere, hvis foreslåede brug af IPD er af ikke-kommerciel karakter og er godkendt af et internt bedømmelsesudvalg.

En IPD-anmodning vil ikke blive behandlet af CSL, medmindre det foreslåede forskningsspørgsmål søger at besvare et væsentligt og ukendt medicinsk videnskabs- eller patientplejespørgsmål som bestemt af CSL's interne revisionsudvalg.

Den anmodende part skal udføre en passende datadelingsaftale, før IPD bliver gjort tilgængelig.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner